Merck: Keytruda improves survival in head and neck cancer

(CercleFinance.com) - Merck's Keytruda improved survival as a first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma according to the final analysis of a pivotal Phase 3 trial, the US drugmaker said on Friday.


The new findings, presented today, showed that Merck's immunotherapy in combination with chemotherapy, reduced the risk of death by 40% in patients, demonstrating significantly longer survival (14.7 months).

Patients with recurrent or metastatic head and neck cancer have a poor prognosis with limited treatment options, Merck said. These findings underscore Keytruda's potential, the company pointed out.

Copyright (c) 2019 CercleFinance.com. All rights reserved.